Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer

T. Wollenweber, L. Zisser, E. Kretschmer-Chott, M. Weber, B. Grubmüller, G. Kramer, SF. Shariat, M. Mitterhauser, S. Schmitl, C. Vraka, AR. Haug, M. Hacker, M. Hartenbach, S. Rasul

. 2021 ; 28 (5) : 3692-3704. [pub] 20210923

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22003677

BACKGROUND: [177Lu]Lu-PSMA-617 radioligand therapy (PSMA-RLT) could affect kidney and salivary gland functions in metastatic castration-resistant prostate cancer (mCRPC) patients. METHODS: We retrospectively analyzed clinical, renal, and salivary scintigraphy data and salivary [68Ga]Ga-PSMA-11 ligand PET scan measures such as metabolic volume and SUVmax values of 27 mCRPC men (mean age 71 ± 7 years) before and 4 weeks after receiving three cycles of PSMA-RLT every 4 weeks. Twenty-two patients additionally obtained renal and salivary scintigraphy prior to each cycle. A one-way ANOVA, post-hoc Scheffé test and Cochran's Q test were applied to assess organ toxicity. RESULTS: In total, 54 PSMA PET scans, 98 kidney, and 98 salivary scintigraphy results were evaluated. There were no significant differences for the ejection fraction, peak time, and residual activity after 5 min for both parotid and submandibular glands prior to each cycle and 4 weeks after the last cycle. Similarly, no significant differences in serum creatinine and renal scintigraphy parameters were observed prior to each cycle and 4 weeks after the last treatment. Despite there being no changes in the metabolic volume of both submandibular glands, SUVmax values dropped significantly (p < 0.05). CONCLUSION: Results evidenced no alterations in renal function and only minimal impairment of salivary function of mCRPC patients who acquired an intense PSMA-RLT regimen every 4 weeks.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003677
003      
CZ-PrNML
005      
20220127150004.0
007      
ta
008      
220113s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/curroncol28050315 $2 doi
035    __
$a (PubMed)34590608
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Wollenweber, Tim $u Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, Austria
245    10
$a Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer / $c T. Wollenweber, L. Zisser, E. Kretschmer-Chott, M. Weber, B. Grubmüller, G. Kramer, SF. Shariat, M. Mitterhauser, S. Schmitl, C. Vraka, AR. Haug, M. Hacker, M. Hartenbach, S. Rasul
520    9_
$a BACKGROUND: [177Lu]Lu-PSMA-617 radioligand therapy (PSMA-RLT) could affect kidney and salivary gland functions in metastatic castration-resistant prostate cancer (mCRPC) patients. METHODS: We retrospectively analyzed clinical, renal, and salivary scintigraphy data and salivary [68Ga]Ga-PSMA-11 ligand PET scan measures such as metabolic volume and SUVmax values of 27 mCRPC men (mean age 71 ± 7 years) before and 4 weeks after receiving three cycles of PSMA-RLT every 4 weeks. Twenty-two patients additionally obtained renal and salivary scintigraphy prior to each cycle. A one-way ANOVA, post-hoc Scheffé test and Cochran's Q test were applied to assess organ toxicity. RESULTS: In total, 54 PSMA PET scans, 98 kidney, and 98 salivary scintigraphy results were evaluated. There were no significant differences for the ejection fraction, peak time, and residual activity after 5 min for both parotid and submandibular glands prior to each cycle and 4 weeks after the last cycle. Similarly, no significant differences in serum creatinine and renal scintigraphy parameters were observed prior to each cycle and 4 weeks after the last treatment. Despite there being no changes in the metabolic volume of both submandibular glands, SUVmax values dropped significantly (p < 0.05). CONCLUSION: Results evidenced no alterations in renal function and only minimal impairment of salivary function of mCRPC patients who acquired an intense PSMA-RLT regimen every 4 weeks.
650    _2
$a senioři $7 D000368
650    _2
$a dipeptidy $7 D004151
650    _2
$a heterocyklické sloučeniny monocyklické $7 D006573
650    _2
$a lidé $7 D006801
650    _2
$a ledviny $x diagnostické zobrazování $x fyziologie $7 D007668
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prostatický specifický antigen $7 D017430
650    12
$a nádory prostaty rezistentní na kastraci $7 D064129
650    _2
$a radiofarmaka $7 D019275
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a slinné žlázy $x diagnostické zobrazování $7 D012469
655    _2
$a časopisecké články $7 D016428
700    1_
$a Zisser, Lucia $u Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, Austria
700    1_
$a Kretschmer-Chott, Elisabeth $u Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, Austria
700    1_
$a Weber, Michael $u Department of Biomedical Imaging and Image-Guided Therapy, Division of General Radiology, Medical University of Vienna, 1090 Vienna, Austria
700    1_
$a Grubmüller, Bernhard $u Department of Urology, Medical University of Vienna, 1090 Vienna, Austria
700    1_
$a Kramer, Gero $u Department of Urology, Medical University of Vienna, 1090 Vienna, Austria
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Medical University of Vienna, 1090 Vienna, Austria $u Department of Urology, Weill Cornell Medical College, New York, NY 10065, USA $u Department of Urology, Second Faculty of Medicine, Charles University, 15006 Prague, Czech Republic $u Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, 119991 Moscow, Russia $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
700    1_
$a Mitterhauser, Markus $u Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, Austria $u Ludwig Boltzmann Institute Applied Diagnostics, 1090 Vienna, Austria
700    1_
$a Schmitl, Stefan $u Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, Austria
700    1_
$a Vraka, Chrysoula $u Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, Austria
700    1_
$a Haug, Alexander R $u Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, Austria $u Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Medical University of Vienna, 1090 Vienna, Austria
700    1_
$a Hacker, Marcus $u Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, Austria
700    1_
$a Hartenbach, Markus $u Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, Austria
700    1_
$a Rasul, Sazan $u Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, Austria
773    0_
$w MED00165427 $t Current oncology (Toronto, Ont.) $x 1718-7729 $g Roč. 28, č. 5 (2021), s. 3692-3704
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34590608 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127150001 $b ABA008
999    __
$a ok $b bmc $g 1751207 $s 1154826
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 28 $c 5 $d 3692-3704 $e 20210923 $i 1718-7729 $m Current oncology $n Curr. oncol. $x MED00165427
LZP    __
$a Pubmed-20220113

Find record

Citation metrics

Archiving options